Drug intelligence / Profile preview

SK-1405

Development stage: Phase 2
Lead developer: Sanwa Kagaku Kenkyusho
Modality: Small Molecules
Administration: Oral

Overview

SK-1405 is an oral small molecule drug developed for the treatment of pruritus, particularly uremic pruritus in patients with renal failure. The drug has been under clinical development in Japan, with Sanwa Kagaku Kenkyusho and UBE Corp. involved as developers. Its primary indication is for skin and musculoskeletal diseases related to pruritus, especially in hemodialysis patients[1][2][3][7]. The precise mechanism of action has not been explicitly stated in public sources; however, clinical trials have focused on receptor occupancy studies and efficacy for uremic pruritus[4][5].

Other names: regorafenib + TAS-102-Sanwa Kagaku Kenkyusho Co., Ltd.-pruritus

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on SK-1405.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SK-1405.

Explore the full profile